文档介绍：强化抗血小板治疗新证据解读
每个临床研究均显示***吡格雷75mg的显著优越性 Each trial shows significant superiority of Clopidogrel 75mg
Establishing long-term efficacy of Plavix in PCI
Establishing superior long-term efficacy and safety of Plavix compared with ASA in first large-scale trial in atherothrombois
Establishing Plavix on top of standard therapy* in largest-ever ACS (NSTEMI, UA) trial
CAPRIE
(n=19,185)
CURE
(n=12,562)
CREDO
(n=2,116)
Establishing early efficacy of Plavix in acute STEMI
CLARITY
(n=)
Establishing mortality benefit of Plavix in acute STEMI
COMITT/CCS-2
(n=46’000)
CHARISMA
(n~15,000)
Establishing long term efficacy of Plavix in patient at high risk of atherothrombotic events
ACTIVE
(n~15,000)
Establishing efficacy of Plavix in patients with atrial fibrillation
* Including ASA
CLopidogrel as Adjunctive ReperfusIon TherapY – Thrombolysis In Myocardial Infarction (TIMI) 28
***吡格雷作为再灌注疗法的辅助治疗——
心肌梗死的溶栓治疗（TIMI）28
CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY) – TIMI 28 Trial Results
目的: 本试验旨在研究急性ST段抬高心梗患者在溶栓和其他标准治疗的基础上加用***吡格雷是否对血管造影结果和临床预后产生益处
研究的组织和病例入组
TIMI研究组 Eugene Braunwald, MD
Brigham and Women’s Hospital Christopher P. Cannon, MD
Harvard Medical School Marc S. Sabatine, MD, MPH
Amy C. McCagg, MBA
入组国家
Spain
France
Canada
Belgium
Russia
Germany
UK
Israel
Inclusion criteria
Age 1875 years
STEMI within 12 hours
Planned treatment with fibrinolytic
Major exclusion criteria
Clopidogrel within 7 days
Planned clopidogrel or GPIIb/IIIa before angiography
Contraindications to thrombolysis (stroke, ICH, brain tumor)
Cardiogenic shock
Intention of angiography within 48 hours
CABG, creatinine > mg/dL, hepatic insufficiency, platelets
67 kg and >4000 U bolus UFH; >67 kg and >5000 U bolus > mg/kg subcutaneous of enoxaparin
Inclusion/Exclusion Criteria1
FOR INTERNAL USE ONLY
Primary endpoint:
Composite of occluded infarct related artery (TFG 0/1) on pre-discharge angiogram, or death or MI bef